Amphotericin B is an amphoteric polyene antibiotic which has been the mainstay of therapy against the systemic mycoses since the late 1950s (3) . Although it can be a life-saving drug, its use is limited by significant toxic reactions: fever, malaise, anorexia, phlebitis, azotemia, hypokalemia, and anemia occur commonly (3) (4) (5) 11) . The anemia is normocytic and normochromic, with a reticulocyte count inappropriately low for the degree of hemoglobin reduction (4) . Although there is some decrease in erythrocyte survival associated with the early stages of amphotericin B treatment of systemic mycoses (4), the cause for the amphotericininduced anemia appears to be reduced erythrocyte production. This poor erythroid production could result either from a direct toxic effect of amphotericin on the marrow, or secondary to a suppression of erythropoietin production by amphotericin.
In this study, we measured erythropoietin levels in serum and urine of patients at the nadir of their amphotericin-induced anemia. The degree of anemia was sufficient to stimulate elevated erythropoietin levels if the anemia had resulted from direct drug inhibition of marrow production. In contrast, if amphotericin caused anemia by inhibiting normal erythropoietin production, the levels would be low.
MATERIALS AND METHODS
The study subjects all received amphotericin B therapy for systemic mycoses, treatment occurring either at the Clinical Center, National Institutes of Health, or at the Hospital of the University of Pennsylvania. Table 1 On the day of assay 5 ml of serum was obtained and frozen at -20'C, and a 24-h urine collection was begun.
On completion of the collection, both specimens were shipped on dry ice to the Cardeza Foundation laboratory for assay. The erythropoietin assay utilized has been described in detail elsewhere (8) . Briefly, adult mice are rendered polycythemic by transfusion (to suppress endogenous erythropoietin production) and then injected subcutaneously with 1.0 ml of the material to be assayed. In the current study, this material consisted of undiluted serum or urine concentrated 50-fold by dialysis against carbowax. A 0. The minimum concentration of erythropoietin which the assay can detect is >0.05 U/ml of serum and >1.5 U/24 h of urine. Only one of the patients (no. 3) had a concentration in serum or urine which exceeded this threshold (Table 1) . His amphotericin treatment had ended 30 days before specimens were ANTIMICROB. AGENTS CHEMOTHER.
obtained for assay, a time interval during which hematocrit recovery often has begun (1) . In all other patients, at a point where the degree of anemia would be expected to stimulate the production of high erythropoietin levels, none could be detected in either serum or 24-h urine collections. DISCUSSION Anemia occurs in more than 95% of patients requiring prolonged amphotericin B therapy (4, 10) . In one study, the mean hematocrit fell from 41% before therapy to 27% at the completion of therapy (4) . Defective iron reutilization is present in many systemic mycotic infections and may in part be responsible for their anemia of chronic infection (6, 7). However, the anemia of amphotericin B therapy is usually time related to drug administration and not to the underlying disease, and so far the characteristic combination of a low serum iron and increased iron stores in the bone marrow has not been described.
Another pathogenic possibility is hemolysis with shortened erythrocyte survival caused by the direct action of amphotericin on circulating cells (9) . However, Brandriss et al. have reported that patients had a slightly reduced erythrocyte survival prior to initiation of amphotericin B therapy (thought to be related to their systemic fungal infections), and no further decrease occurred whem amphotericin was begun (4). Furthermore, the hemolytic process would be expected to result in reticulocytosis instead of the reticulocytopenia usually seen. Consequently, it has been concluded that the anemia is caused by a drug-induced suppression of erythrocyte production rather than an increased rate of destruction. This conclusion is supported by the fact that the anemia is normocytic and normochromic, and that bone marrow examination, reticulocyte counts, and ferrokinetic studies fail to reveal a compensatory erythropoietic response to the anemia.
A direct toxic suppression of bone marrow cell production by amphotericin B is a possibility. However, the results reported here indicate that the anemia is associated with a reduced production of the stimulating hormone erythropoietin rather than with the increased production usually seen in primary hypoplastic anemias. None of our patients had a detectable level of erythropoietin in serum or urine at a time when the mean hematocrit value was 26%. A normal erythropoietin response at that degree of anemia raises the serum level to 0.3 to 1.0 U/ml and the daily excretion of erythropoietin in urine to about 10 to 30 U (1, 7, 8) . The laboratory performing the tests in this report has observed such elevated levels of erythropoietin in essentially all patients with hematocrits in this range, unless renal impairment has been present. Consequently, it appears that the anemia of amphotericin B therapy is caused by a relative failure of erythropoietin production. It has been reported variously that chronic active infection causes a severe reduction (12), a borderline reduction (7), and no reduction (2) in erythropoietin. However, at the time when the patients had developed anemia and had no measurable erythropoietin in their blood, they had no clinical evidence of active infection. Two of the patients were also receiving 5-fluorocytosine, a drug which can induce anemia by direct suppression of marrow production. Such suppression, however, should have been an additional stimulus for erythropoietin production and cannot explain our findings.
A direct inhibition of the assay by amphotericin in the serum or urine being assayed is unlikely because four of the patients tested had completed therapy 3 to 30 days before specimens were obtained for assay, so that the maximum possible amount of amphotericin injected was trivial.
The observed erythropoietin deficiency anemia mimics that of chronic renal failure and may be secondary to amphotericin's nephrotoxic action. Although Brandriss et al. found no correlation between the degrees of azotemia and anemia (4), Miller and Bates (10) reported that their patients with the most marked increase in blood urea nitrogen during therapy had the greatest decrease in hematocrit (P < 0.01). In our patients, the mean blood urea nitrogen of 25.2 and creatinine of 1.6 mg/dl were only mildly increased, and it seems unlikely that this degree of renal damage or uremia could be responsible for the severe anemia. However, it has to be conceded that we do not know the exact mode or site of erythropoietin production in the kidneys and it is possible that amphotericin exerts a selective inhibition of erythropoietin production there.
Regardless of the mechanism, erythrop9ietin
was undetectable in our patients at the nadir of their anemia, and this deficiency appears to make a major contribution to the anemia.
